Anika Therapeutics (ANIK) Total Non-Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Total Non-Current Liabilities data on file, last reported at $44.8 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $44.8 million, up 7.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.8 million (up 7.95% YoY), and the FY2025 annual result was $46.1 million, down 3.91% from the prior year.
• Total Non-Current Liabilities declined to $44.8 million in Q1 2026 per ANIK's latest filing, from $46.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $67.4 million in Q2 2022 and troughed at $39.3 million in Q2 2025.
• A 5-year average of $52.8 million and a median of $54.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 13.39% in 2022 and fell as far as 33.62% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $63.2 million in 2022, then decreased by 8.24% to $58.0 million in 2023, then fell by 17.22% to $48.0 million in 2024, then fell by 3.91% to $46.1 million in 2025, then retreated by 2.92% to $44.8 million in 2026.
• Business Quant data shows ANIK's Total Non-Current Liabilities at $44.8 million in Q1 2026, $46.1 million in Q4 2025, and $41.9 million in Q3 2025.